MedImmune Gains Anti-CD28 Biologic In Deal With Japan Tobacco
This article was originally published in PharmAsia News
MedImmune is bolstering its research pipeline for treatments targeting inflammatory diseases, announcing its second licensing deal this month for technology in the therapeutic class. Under the latest deal with Japan Tobacco, announced Dec. 28, the company intends to develop a monoclonal antibody targeting CD28 receptor pathways for treatment of inflammatory diseases
You may also be interested in...
Collaboration includes Phase I monoclonal antibody targeting interleukin-5 and BioWa’s antibody-enhancing technology.